Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARES: Simvastatin with Nivolumab + Oxaliplatin-based Chemotherapy in ARID1A-mutated Gastrooesophageal Carcinoma
2024-519591-39-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of simvastatin in gastroesophageal junction adenocarcinoma (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: 1-year progression-free survival rate. Planned start Nov 2025; status: authorised.
02
Drugs
simvastatin
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-519591-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519591-39-00.